Table 5.
MRD assessments at the 6-month follow-up.
| MRD response rates | Venetoclax +LDAC (n = 143a) | Placebo + LDAC (n = 68a) | P value |
|---|---|---|---|
| Best MRD value, n (%) | |||
| <10−3 | 12 (8.4) | 2 (2.9) | – |
| <10−4 | 9 (6.3) | 0 | – |
| MRD <10−3 and CR/CRi response, n (%) [95% CI] | 9 (6.3) [2.9, 11.6] | 1 (1.5) [0.0, 7.9] | 0.118 |
| MRD <10−4 and CR/CRi response, n (%) [95% CI] | 6 (4.2) [1.6, 8.9] | 0 | 0.088 |
| MRD <10−3 and CR/CRi response at end of cycle 4, n (%) [95% CI] | 4 (2.8) [0.8, 7.0] | 0 | 0.173 |
| MRD <10−4 and CR/CRi response at end of cycle 4, n (%) [95% CI] | 3 (2.1) [0.4, 6.0] | 0 | 0.218 |
CI confidence interval, CR complete remission, CRi complete remission with incomplete hematologic recovery, LDAC low-dose cytarabine, MRD minimal residual disease.
aBy the 6-month cut-off, 44 patients in the placebo + LDAC arm and 113 patients in the venetoclax +LDAC arm had an MRD assessment.